Chronic Kidney Disease Improvement in Research and Treatment Act of 2021

Issues related to End Stage Renal Disease Perspective Payment System HR 7878/S 4307, Kidney Health Connect Act (all provisions) Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act H.R. 8063, Repair Abuses of MSP Payments Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 8295 Fiscal Year 2023 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Client expense: $960,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R. 1946, S. 1873. Medicare Multi-Cancer Early Detection Screening Coverage; H.R. 2617-accelerated approval in the Omnibus year end H.R. 4065, S. 1971 (section 101), P.L. 117-328, H.R. 2617 Kidney disease screening, Expanding Medicare annual wellness benefit to include kidney disease screening. H.R. 5260 - Reduced Costs and Continued Cures Act; HR. 5376- Inflation Reduction Act; Build Back Better Act; CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure; Preventative healthcare services and screenings Issues related to preventative services and screenings for underrepresented communities IRA implementation, Pub. L. 117-169 Medicare Reform(s); Issues related to Medicare Part B and Part D pricing reform. General issues related to patient access to rare disease therapies, Part B and Part D drugs; issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; value-based payment arrangements; efforts to improve coding, coverage, and access for rare disease therapies; issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; general issues related to diagnostic reimbursement

Client expense: $1,170,000 · Firm income: Not reported

Home dialysis/home therapies issues; H.R. 5426 - Improving Access to Dialysis Act; H.R. 4065 and S. 1971 - Chronic Kidney Disease Improvement Act; H.R. 2903 and S. 1512 - CONNECT Act; H.R. 1255 and S. 377 - Living Donor Protection Act; H.R. 2568 and S. 1220 - US Cadet Nurse Corps Service Recognition Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues and legislation relating to kidney disease. Policies that impact kidney care providers and patients. 2022 Labor, HHS, Education and Related Agencies Appropriations bill (KidneyX Program) S.1971 and H.R.4065 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S.377 and H.R.1255 - Living Donor Protection Act of 2021 S. 4750 and H.R. 8594 Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.

Client expense: $310,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.

Client expense: $310,000 · Firm income: Not reported

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S. 377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F); H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Issues related to End Stage Renal Disease and Chronic Kidney Disease; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F); H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Assist the Administration during Covid-19 epidemic on how to help and protect dialysis patients; Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age - (H.R. 1676) - The Jack Reynolds Memorial Medigap Expansion Bill; Protect organ donors by urging passage of the Living Donor Protection Act of 2021 (H.R. 1255/S. 377); Protect dialysis patient access to charitable premium assistance; Ensure ESRD patients retain access to private insurance; Support ESRD care coordination - The BETTER Kidney Care Bill (H.R. 4942/S. 2649); Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support the Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 4065/S. 1971); Assist the Administration about Prioritizing Prevention, Home Dialysis; and Urge Congress to protect access to private insurance H.R. 8594/S. 4750 - The Restore Protections for Dialysis Patients Act.

Client expense: $450,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 - The Inflation Reduction Act of 2022; General issues related to patient access to rare disease therapies, Part B and Part D drugs; Issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; Value-based payment arrangements; Efforts to improve coding, coverage, and access for rare disease therapies; Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement S. 1873/H.R. 1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 Issues related to preventative services and screenings for underrepresented communities H.R 4065/S. 1971 (Section 101) - Expanding Medicare annual wellness benefit to include kidney disease screening CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure General issues related to diagnostic reimbursement

Client expense: $930,000 · Firm income: Not reported

ESRD prospective payment system CY 2022 proposed rule and guidance; Medicare Advantage Program; S. 1971/H.R. 4065 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021."

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ESRD prospective payment system, quality incentive program, ESRD Treatment Choices Model, Medicare Advantage program, COVID-19 relief guidance; S. 1971/H.R. "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021"; HHS transplant ecosystem request for information.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

Assist the Administration during Covid-19 epidemic on how to help and protect dialysis patients; Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age - (H.R. 1676) - The Jack Reynolds Memorial Medigap Expansion Bill; Protect organ donors by urging passage of the Living Donor Protection Act of 2021 (H.R. 1255/S. 377); Protect dialysis patient access to charitable premium assistance; Ensure ESRD patients retain access to private insurance; Support ESRD care coordination - The BETTER Kidney Care Bill (H.R. 4942/S. 2649); Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support the Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 4065/S. 1971); Assist the Administration about Prioritizing Prevention, Home Dialysis; and Urge Congress to protect access to private insurance H.R. 8594/S. 4750 - The Restore Protections for Dialysis Patients Act.

Client expense: $400,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.

Client expense: $300,000 · Firm income: Not reported

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.

Client expense: $300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 - The Inflation Reduction Act of 2022; General issues related to patient access to rare disease therapies, Part B and Part D drugs; Issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; Value-based payment arrangements; Efforts to improve coding, coverage, and access for rare disease therapies; Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement S. 1873/H.R. 1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 Issues related to preventative services and screenings for underrepresented communities H.R 4065/S. 1971 (Section 101) - Expanding Medicare annual wellness benefit to include kidney disease screening CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure General issues related to diagnostic reimbursement

Client expense: $910,000 · Firm income: Not reported

H.R. 8594/S. 4750, the Restore Protections for Dialysis Patients Act H.R. 7845/ the NIH Clinical Trial Diversity Act H.R. 1255/S. 377, the Living Donor Protection Act H.R. 1676, the Jack Reynold Medigap Expansion Act H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021 Health disparities S. 1002, the Junk Plan Accountability and Disclosure Act of 2021 H.R. 4065/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021. H.R. 3893, the CARE for All Kidneys Act FY 2023, Labor-HHS-Education Appropriations Act H.R. 7585, the Health Equity and Accountability Act of 2022 (HEAA) H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act H.R. 7667, the Food and Drug Amendments of 2022 H.R. 7506, the New Era for Preventing End-Stage Kidney Disease Act of 2022 Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and Other Revisions to Medicare Enrollment and Eligibility Rules Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry Request for Information on ways to strengthen and improve the Organ Procurement and Transplantation Network

Client expense: $150,000 · Firm income: Not reported

Issues related to End Stage Renal Disease Perspective Payment System HR 7878/S 4307, Kidney Health Connect Act (all provisions) Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act H.R. 8063, Repair Abuses of MSP Payments Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 S. 368, Telehealth Modernization Act, all provisions MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 8295 Fiscal Year 2023 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Issues related to End Stage Renal Disease Perspective Payment System HR 7878/S 4307, Kidney Health Connect Act (all provisions) Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act H.R. 8063, Repair Abuses of MSP Payments Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 8295 Fiscal Year 2023 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Issues and legislation relating to kidney disease. Policies that impact kidney care providers and patients. 2022 Labor, HHS, Education and Related Agencies Appropriations bill (KidneyX Program) S.1971 and H.R.4065 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S.377 and H.R.1255 - Living Donor Protection Act of 2021 S. 4750 and H.R. 8594 Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S. 377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22; H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease and Chronic Kidney Disease; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22; H.R. 8594/S. 4750, Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Home dialysis/home therapies issues; H.R. 5426 - Improving Access to Dialysis Act; H.R. 4065 and S. 1971 - Chronic Kidney Disease Improvement Act; H.R. 2903 and S. 1512 - CONNECT Act; H.R. 1255 and S. 377 - Living Donor Protection Act; H.R. 2568 and S. 1220 - US Cadet Nurse Corps Service Recognition Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)

ESRD prospective payment system CY 2022 proposed rule and guidance; Medicare Advantage Program; S. 1971/H.R. 4065 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021."

Client expense: Not reported · Firm income: $12,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ESRD prospective payment system, quality incentive program, ESRD Treatment Choices Model, Medicare Advantage program, COVID-19 relief guidance; S. 1971/H.R. "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021"; HHS transplant ecosystem request for information.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

H.R. 1255/S. 377, the Living Donor Protection Act H.R. 1676, the Jack Reynold Medigap Expansion Act H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021 Health disparities S. 1002, the Junk Plan Accountability and Disclosure Act of 2021 H.R. 4065/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021. H.R. 3893, the CARE for All Kidneys Act FY 2023, Labor-HHS-Education Appropriations Act H.R. 7585, the Health Equity and Accountability Act of 2022 (HEAA) H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act H.R. 7845, NIH Clinical Trial Diversity Act of 2022 H.R. 7667, the Food and Drug Amendments of 2022 H.R. 7506, the New Era for Preventing End-Stage Kidney Disease Act of 2022 Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and Other Revisions to Medicare Enrollment and Eligibility Rules Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry Request for Information on ways to strengthen and improve the Organ Procurement and Transplantation Network

Client expense: $130,000 · Firm income: Not reported

Issues and legislation relating to kidney disease. Policies that impact kidney care providers and patients. 2022 Labor, HHS, Education and Related Agencies Appropriations bill (KidneyX Program) S.1971 and H.R.4065 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S.377 and H.R.1255 - Living Donor Protection Act of 2021

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; S.377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22

Client expense: Not reported · Firm income: $70,000

Issues related to End Stage Renal Disease and Chronic Kidney Disease; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; Medicare Secondary Payer; H.R. 7878/S. 4307 Kidney Health Connect Act of 2022; Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Proposed Rule, issued 6/21/22

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Assist the Administration during Covid-19 epidemic on how to help and protect dialysis patients; Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age - (H.R. 1676) - The Jack Reynolds Memorial Medigap Expansion Bill; Protect organ donors by urging passage of the Living Donor Protection Act of 2021 (H.R. 1255/S. 377); Protect dialysis patient access to charitable premium assistance; Ensure ESRD patients retain access to private insurance; Support ESRD care coordination - The BETTER Kidney Care Bill (H.R. 4942/S. 2649); Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support the Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 4065/S. 1971); and Assist the Administration about Prioritizing Prevention, Home Dialysis.

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

Issues related to End Stage Renal Disease Perspective Payment System (no legislation introduced) HR 7878/S 4307, Kidney Health Connect Act (all provisions) Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 Issues related to the Medicare Secondary Payor (MSP) Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 S. 368, Telehealth Modernization Act, all provisions MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 8295 Fiscal Year 2023 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Issues related to End Stage Renal Disease Perspective Payment System (no legislation introduced) HR 7878/S 4307, Kidney Health Connect Act (all provisions) Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 Issues related to the Medicare Secondary Payor (MSP) Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 8295 Fiscal Year 2023 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.

Client expense: $320,000 · Firm income: Not reported

Home dialysis/home therapies issues; H.R. 5426 - Improving Access to Dialysis Act; H.R. 4065 and S. 1971 - Chronic Kidney Disease Improvement Act; H.R. 2903 and S. 1512 - CONNECT Act; H.R. 1255 and S. 377 - Living Donor Protection Act; H.R. 2568 and S. 1220 - US Cadet Nurse Corps Service Recognition Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)

H.R. 1255/S. 377, the Living Donor Protection Act H.R. 1676, the Jack Reynold Medigap Expansion Act H.R. 526, Ensuring Coverage in Public Health Emergencies Act of 2021 Increasing FMAP (Federal Medicare Assistance Percentage) Health disparities S. 1002, the Junk Plan Accountability and Disclosure Act of 2021 Organ Procurement Organizations Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations Part D Payment Modernization (PDM) Model for plan year 2022 Charitable Premium Assistance H.R. 3912/S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2021. H.R. 3893, the CARE for All Kidneys Act FY 2022, Labor-HHS-Education Appropriations Act

Client expense: $190,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); Implementation of American Rescue Plan Act of 2021 (PL 117-2); Extension of the Medicare Sequester; S. 748, Medicare Sequester Relief Act; Telehealth issues related to COVID-19, including audio-only; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; S.377/H.R. 1255, Living Donor Protection Act; H.R. 1676, Jack Reynolds Memorial Medigap Expansion Act H.R. 3893, Coordination, Accountability, Research and Equity for All Kidneys Act of 2021 (CARE for All Kidneys Act); H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs; Kildee/Wenstrup draft legislation to expand the ability of renal dialysis facilities to serve as originating sites for Medicare telehealth services

Client expense: Not reported · Firm income: $70,000

Issues related to End Stage Renal Disease and Chronic Kidney Disease; Implementation of American Rescue Plan Act of 2021 (PL 117-2); Extension of the Medicare Sequester; S. 748, Medicare Sequester Relief Act; Telehealth issues related to COVID-19; H.R. 1999, To delay and offset the sequester under the Statutory Pay-As-You-Go Act of2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes; End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and utilization of calcimimetic drugs S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; H.R. 4065, To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes; Kildee/Wenstrup draft legislation to expand the ability of renal dialysis facilities to serve as originating sites for Medicare telehealth services

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues and legislation relating to kidney disease. Policies that impact kidney care providers and patients. 2022 Labor, HHS, Education and Related Agencies Appropriations bill (KidneyX Program) S.1971 and H.R.4065 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S.377 and H.R.1255 - Living Donor Protection Act of 2021

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

ESRD prospective payment system CY 2022 proposed rule and guidance; Medicare Advantage Program; S. 1971/H.R. 4065 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021."

Client expense: Not reported · Firm income: $15,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.

Client expense: $320,000 · Firm income: Not reported

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 Issues related to the Medicare Secondary Payor (MSP) Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 S. 368, Telehealth Modernization Act, all provisions MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program Fiscal Year 2022 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Client expense: $1,280,000 · Firm income: Not reported

Issues related to supply chain Issues related to end stage renal disease calcimimetics utilization Issues related to Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) Issues related to Transitional Drug Add-on Payment Adjustment (TDAPA) Issues related to nursing shortages H.R. 4942/S. 2649, Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act H.R. 1676, The Jack Reynolds Memorial Medigap Expansion Act H.R. 5426, Improving Access to Home Dialysis Act of 2021 Issues related to the Medicare Secondary Payor (MSP) Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options Emergency response related to COVID-19 MedPAC CY22 report to Congress, Medicare end-stage renal disease perspective payment system base rate recommendation S. 1971/ H.R. 4065 Chronic Kidney Disease Improvement in Research and Treatment Act, all provisions ESRD facilities serving as originating sites for telehealth services under the Medicare program Fiscal Year 2022 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations bill, provision relating to KidneyX funding H.R. 6000, CURES 2.0 Act, provisions related to dialysis

Client expense: $1,280,000 · Firm income: Not reported

ESRD prospective payment system, quality incentive program, ESRD Treatment Choices Model, Medicare Advantage program, COVID-19 relief guidance; S. 1971/H.R. "Chronic Kidney Disease Improvement in Research and Treatment Act of 2021"; HHS transplant ecosystem request for information.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

Assist the Administration during Covid-19 epidemic on how to help and protect dialysis patients; Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age - (H.R. 1676) - The Jack Reynolds Memorial Medigap Expansion Bill; Protect organ donors by urging passage of the Living Donor Protection Act of 2021 (H.R. 1255/S. 377); Protect dialysis patient access to charitable premium assistance; Ensure ESRD patients retain access to private insurance; Support ESRD care coordination - The BETTER Kidney Care Bill (H.R. 4942/S. 2649); Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support the Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 4065/S. 1971); and Assist the Administration about Prioritizing Prevention, Home Dialysis.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office